We are live on ! Find out more
MACK

Merrimack Pharmaceuticals, Inc.
MACK

Delisted

MACK was delisted on the 17th of May, 2024.

Back to rankings

143 hedge funds and large institutions have $657M invested in Merrimack Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 45 increasing their positions, 44 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 20

39% more capital invested

Capital invested by funds: $474M → $657M (+$183M)

8% more funds holding

Funds holding: 132 → 143 (+11)

2% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 44

31% less call options, than puts

Call options by funds: $1.79M | Put options by funds: $2.58M

Holders
143
Holders Change
+11
Holders Change %
+8.33%
% of All Funds
3.81%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
33
Increased
45
Reduced
44
Closed
20
Calls
$1.79M
Puts
$2.58M
Net Calls
-$793K
Net Calls Change
-$2.86M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$9.22M
2
BIT
BlackRock Institutional Trust
California
+$6.6M
3
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$5.39M
4
TC
TFS Capital
Pennsylvania
+$4.41M
5
BFA
BlackRock Fund Advisors
California
+$3.74M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$13.5M
2
State Street
State Street
Massachusetts
-$4.29M
3
Jane Street
Jane Street
New York
-$2.83M
4
SIP
Stoneridge Investment Partners
Pennsylvania
-$2.59M
5
New York State Common Retirement Fund
New York State Common Retirement Fund
New York
-$1.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
76
American International Group
New York
$698K -$33.7K -463 -6%
Citigroup
77
Citigroup
New York
$647K +$361K +4,955 +213%
BG
78
BlackRock Group
United Kingdom
$629K +$469K +6,439 +1,022%
DekaBank Deutsche Girozentrale
79
DekaBank Deutsche Girozentrale
Germany
$621K -$46.3K -635 -8%
DCM
80
Driehaus Capital Management
Illinois
$582K +$477K +6,544 New
EMG
81
Ellington Management Group
Connecticut
$558K +$457K +6,279 New
Citadel Advisors
82
Citadel Advisors
Florida
$553K -$1.02M -14,019 -69%
BC
83
Birchview Capital
Vermont
$478K +$392K +5,376 New
CA
84
Commerzbank Aktiengesellschaft
Germany
$464K +$380K +5,220 New
T. Rowe Price Associates
85
T. Rowe Price Associates
Maryland
$461K +$140K +1,920 +59%
Federated Hermes
86
Federated Hermes
Pennsylvania
$452K -$370K -5,084 -50%
Bank of America
87
Bank of America
North Carolina
$452K -$63.3K -869 -15%
State Board of Administration of Florida Retirement System
88
State Board of Administration of Florida Retirement System
Florida
$427K – – –
Public Employees Retirement Association of Colorado
89
Public Employees Retirement Association of Colorado
Colorado
$424K +$348K +4,772 New
PPA
90
Parametric Portfolio Associates
Washington
$416K +$153K +2,107 +82%
FM
91
Family Management
New York
$367K +$120K +1,653 +67%
JEW
92
Jamison Eaton & Wood
New Jersey
$356K -$290K -3,975 -50%
MCM
93
Manchester Capital Management
Vermont
$339K – – –
AMG
94
Asset Management Group
Connecticut
$333K – – –
PA
95
Pinnacle Associates
New York
$308K – – –
PWMAG
96
Pinnacle Wealth Management Advisory Group
New Jersey
$308K +$252K +3,463 New
WP
97
WMS Partners
Maryland
$289K – – –
CEP
98
Chicago Equity Partners
Illinois
$244K -$166K -2,274 -45%
PPSG
99
Princeton Portfolio Strategies Group
New Jersey
$234K +$192K +2,631 New
CHAM
100
Clear Harbor Asset Management
Connecticut
$231K -$2.77K -38 -1%
2 3
4
5 6

MACK Hedge Fund Activity: Q4 2014 in Review

143 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2014, worth a combined $657M — up 39% from $474M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new MACK positions and 20 closed out — a net gain of 13 holders — while 45 added to existing stakes and 44 trimmed.

The largest buyer was Vanguard Group, adding an estimated $9.22M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $13.5M sold.

  • 143 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2014, up from 132 in Q3 2014.
  • Funds reported $657M of Merrimack Pharmaceuticals, Inc. stock for Q4 2014, up 39% quarter-over-quarter.
  • 33 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2014 and 20 closed out, a net change of +13 holders.
  • The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2014 was Vanguard Group, an estimated $9.22M added.
  • The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2014 was Consonance Capital Management, an estimated $13.5M sold.

Based on aggregated 13F filings for Q4 2014.